CA
NZ
UK
AU
IND
US
…
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Roche Holding Ltd is a global Swiss healthcare company operating pharmaceuticals and diagnostics, with major activities in oncology and immunology. Long-term growth may be supported by aging populations, rising demand for molecular and point-of-care testing, and its R&D pipeline and portfolio of established drugs, while diversified revenue across pharma and diagnostics provides earnings resilience. Key risks include patent expiries and biosimilar competition, clinical trial or regulatory setbacks, pricing and reimbursement pressure, and exposure to currency and geopolitical fluctuations.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 16973.00M | 11793.00M | 14079.00M | 16327.00M | 17398.00M |
| Minority interest | -919.00M | -910.00M | -860.00M | -1110.00M | -1005.00M |
| Net income | 12880.00M | 8277.00M | 11498.00M | 12421.00M | 13930.00M |
| Selling general administrative | 15161.00M | 14896.00M | 14881.00M | 12124.00M | 13249.00M |
| Gross profit | 46711.00M | 46112.00M | 44084.00M | 44770.00M | 43154.00M |
| Reconciled depreciation | 3386.00M | 3423.00M | 3464.00M | 3844.00M | 4443.00M |
| Ebit | - | - | - | 21187.00M | 20187.00M |
| Ebitda | - | - | - | 20861.00M | 22260.00M |
| Operating income | 18476.00M | 13417.00M | 15395.00M | 17476.00M | 18155.00M |
| Other operating expenses | - | - | - | 192.00M | 238.00M |
| Interest expense | 1346.00M | 1403.00M | 997.00M | 690.00M | 419.00M |
| Tax provision | 3174.00M | 2606.00M | 1721.00M | 2796.00M | 2463.00M |
| Interest income | 203.00M | 260.00M | 195.00M | 1040.00M | 677.00M |
| Net interest income | -1135.00M | -1151.00M | -814.00M | -673.00M | -414.00M |
| Income tax expense | - | - | - | 2796.00M | 2463.00M |
| Total revenue | 63356.00M | 62395.00M | 60441.00M | 63281.00M | 62801.00M |
| Total operating expenses | 44880.00M | 48978.00M | 45046.00M | 45805.00M | 44646.00M |
| Cost of revenue | 16645.00M | 16283.00M | 16357.00M | 18511.00M | 19647.00M |
| Net income from continuing ops | 13799.00M | 9187.00M | 12358.00M | 13531.00M | 14935.00M |
| Net income applicable to common shares | - | - | - | 12421.00M | 13930.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 100703.00M | 101801.00M | 90468.00M | 88151.00M | 92317.00M |
| Intangible assets | 19321.00M | 17303.00M | 14828.00M | 9685.00M | 12117.00M |
| Other current assets | 374.00M | 225.00M | 223.00M | 574.00M | 382.00M |
| Total liab | 62823.00M | 65640.00M | 57205.00M | 60159.00M | 63972.00M |
| Total stockholder equity | 37880.00M | 36161.00M | 29315.00M | 27992.00M | 24489.00M |
| Other current liab | - | - | 1.00M | 6440.00M | 6231.00M |
| Common stock | - | - | - | 107.00M | 160.00M |
| Capital stock | 107.00M | 107.00M | 107.00M | 107.00M | 160.00M |
| Retained earnings | 48837.00M | 43842.00M | 42347.00M | 38937.00M | 34161.00M |
| Other liab | - | - | - | 6615.00M | 8455.00M |
| Good will | 7492.00M | 7876.00M | 9390.00M | 10820.00M | 10809.00M |
| Other assets | - | - | - | 8651.00M | 8283.00M |
| Cash | 5582.00M | 6975.00M | 5376.00M | 2841.00M | 6850.00M |
| Cash and equivalents | - | - | - | 2150.00M | 1822.00M |
| Total current liabilities | 28001.00M | 27023.00M | 24824.00M | 27239.00M | 38416.00M |
| Net debt | 26054.00M | 27679.00M | 23833.00M | 20360.00M | 24348.00M |
| Short term debt | - | - | - | 2191.00M | 14618.00M |
| Short long term debt | 4206.00M | 3932.00M | 4399.00M | 3960.00M | 15122.00M |
| Other stockholder equity | - | - | - | -11052.00M | -9832.00M |
| Property plant equipment | - | - | - | 24208.00M | 24412.00M |
| Total current assets | 38729.00M | 40036.00M | 33446.00M | 33816.00M | 35627.00M |
| Net tangible assets | - | - | - | 7487.00M | 1563.00M |
| Short term investments | 9894.00M | 10342.00M | 5134.00M | 4776.00M | 6181.00M |
| Net receivables | 12391.00M | 12005.00M | 11636.00M | 13668.00M | 12628.00M |
| Long term debt | 27430.00M | 30722.00M | 24810.00M | 21391.00M | 16076.00M |
| Inventory | 7479.00M | 7606.00M | 7749.00M | 8605.00M | 7715.00M |
| Accounts payable | 4237.00M | 3984.00M | 3524.00M | 4132.00M | 4115.00M |
| Non currrent assets other | 844.00M | 822.00M | 873.00M | 948.00M | 834.00M |
| Non current assets total | 61974.00M | 61765.00M | 57022.00M | 54335.00M | 56690.00M |
| Capital lease obligations | 1555.00M | 1700.00M | 1573.00M | 1193.00M | 1354.00M |
| Long term debt total | - | - | - | 22282.00M | 17101.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 32.00M | -4998.00M | -707.00M | 1127.00M | 363.00M |
| Change to liabilities | - | - | - | 0.00M | 0.00M |
| Total cashflows from investing activities | - | - | - | -3536.00M | -6552.00M |
| Net borrowings | -155.00M | 3819.00M | 5785.00M | -6103.00M | 16348.00M |
| Total cash from financing activities | - | - | - | -16275.00M | -13108.00M |
| Change to operating activities | - | - | - | -2418.00M | -994.00M |
| Net income | 12880.00M | 8277.00M | 11498.00M | 12421.00M | 13930.00M |
| Change in cash | -1393.00M | 1599.00M | 385.00M | -1859.00M | 1123.00M |
| Begin period cash flow | 6975.00M | 5376.00M | 4991.00M | 6850.00M | 5727.00M |
| End period cash flow | 5582.00M | 6975.00M | 5376.00M | 4991.00M | 6850.00M |
| Total cash from operating activities | 18852.00M | 20094.00M | 16095.00M | 18415.00M | 20976.00M |
| Issuance of capital stock | -987.00M | -1130.00M | -1144.00M | 1257.00M | 1406.00M |
| Depreciation | 3386.00M | 3423.00M | 3464.00M | 3844.00M | 4443.00M |
| Other cashflows from investing activities | - | - | - | 51.00M | -73.00M |
| Dividends paid | 7731.00M | 7650.00M | 7590.00M | 7446.00M | 7773.00M |
| Sale purchase of stock | - | - | - | 0.00M | -18991.00M |
| Other cashflows from financing activities | - | - | - | -1469.00M | -1286.00M |
| Change to netincome | - | - | - | 4564.00M | 3589.00M |
| Capital expenditures | 5779.00M | 5009.00M | 4649.00M | 3449.00M | 3693.00M |
| Change in working capital | -1657.00M | 1161.00M | -1107.00M | -8227.00M | -994.00M |
| Stock based compensation | 857.00M | 855.00M | 830.00M | 738.00M | 663.00M |
| Other non cash items | 1337.00M | 1640.00M | 1260.00M | 1131.00M | 722.00M |
| Free cash flow | 13073.00M | 15085.00M | 11446.00M | 13863.00M | 16427.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RHHBY Roche Holding Ltd ADR |
-0.59 0.96% |
60.68 | 23.48 | 16.31 | 5.56 | 8.78 | 4.94 | 14.76 |
| LLY Eli Lilly and Company |
-6.34 0.45% |
1411.20 | 38.16 | 24.15 | 12.72 | 29.95 | 13.31 | 25.43 |
| JNJ Johnson & Johnson |
-2.64 0.97% |
270.56 | 30.96 | 20.79 | 6.58 | 7.55 | 6.84 | 19.73 |
| ABBV AbbVie Inc |
-5.95 2.02% |
288.94 | 74.10 | 16.21 | 7.22 | 50.46 | 8.18 | 27.04 |
| RHHVF Roche Holding AG Participation |
-0.68 0.14% |
485.00 | 24.16 | 16.53 | 5.71 | 8.88 | 4.94 | 14.76 |
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
| Name | Title | Year Born |
|---|---|---|
| Dr. Severin Schwan Ph.D. | CEO & Exec. Director | 1967 |
| Dr. Alan Hippe | Chief Financial & Information Officer | 1967 |
| Ms. Cristina A. Wilbur | Chief People Officer | 1967 |
| Dr. Johannes Carolus Clevers M.D., Ph.D. | Head of Roche Pharma Research & Early Devel. | 1957 |
| Dr. Thomas Schinecker | Chief Exec. Officer of Roche Diagnostics | 1975 |
| Mr. William N. Anderson | Chief Exec. Officer of Roche Pharmaceuticals | 1966 |
| Dr. Bruno Eschli | Head of Investor Relations | NA |
| Ms. Claudia Bockstiegel | Gen. Counsel | 1964 |
| Ms. Pascale Schmidt | Chief Compliance Officer | 1973 |
| Ms. Barbara Schadler | Head of Group Communications | 1962 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.09%
Communication Services
+0.21%
Consumer Cyclical
+1.14%
Consumer Defensive
+0.88%
Energy
-2.61%
Financial Services
+0.70%
Financials
+0.41%
Healthcare
-0.75%
Industrials
+0.35%
Real Estate
+0.57%
Technology
-1.17%
Utilities
+0.05%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...